EGFR and non-small cell lung carcinoma: EGFR TKIs have dramatically improved overall survival outcomes of EGFR-mutant NSCLC patients with a favorable therapeutic ratio due to a logarithmic higher sensitivity of the mutant versus the wild-type receptor.